2013 Gastrointestinal Cancers Symposium

gastrointestinal cancer

Give Your Patients the Latest GI Research News

During the upcoming Gastrointestinal Cancers Symposium, to be held on January 24–26, direct your patients to www.cancer.net/gisymposium, where they can get research highlights from the 2013 Symposium....

pancreatic cancer

Nab-paclitaxel/Gemcitabine Combination Improves Overall Survival in Pancreatic Cancer 

In patients with treatment-naive metastatic pancreatic cancer, the addition of nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) to gemcitabine improved overall survival vs gemcitabine alone, in ...

colorectal cancer

A New Donor Shines with Conquer Cancer Foundation

To support all of our valuable programs for patients and physicians, the Conquer Cancer Foundation of the American Society of Clinical Oncology partners with organizations of every size and scale, and...

colorectal cancer

Outcomes Comparable for Panitumumab and Bevacizumab in Metastatic Colorectal Cancer 

In patients with KRAS wild-type metastatic colorectal cancer, outcomes were comparable whether patients received the epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) or the vas...

colorectal cancer

FOLFOXIRI Plus Bevacizumab Is Superior to FOLFIRI Plus Bevacizumab in Metastatic Colorectal Cancer 

For the treatment of metastatic colorectal cancer, better outcomes were achieved when bevacizumab (Avastin) was added to FOLFOXIRI (leucovorin, fluorouracil [5-FU], oxaliplatin, irinotecan), rather th...

solid tumors
colorectal cancer

Oncogenic Pathway Signatures May Guide Treatment after Colorectal Cancer Resection 

Deregulation of oncogenic signaling pathways was used to molecularly subclassify colorectal cancers into clinically relevant subgroups with both prognostic and predictive implications, in a study from...

solid tumors
breast cancer

Evaluating HER2 Status in Esophageal Cancers: FISH vs Immunohistochemistry 

In screening patients with esophageal cancers for HER2 status, the relative efficiency of immunohistochemistry (IHC) vs fluorescence in situ hybridization (FISH) has been debated. Researchers from the...

solid tumors
colorectal cancer

Colorectal Cancer: A Decade of Progress 

The 2013 Gastrointestinal Cancers Symposium marked the 10th anniversary of the meeting. Richard M. Goldberg, MD, the Klotz Family Chair in Cancer Research, Professor of Medicine, and James Cancer Hosp...

solid tumors
gastroesophageal cancer

Second-line Docetaxel Improves Esophageal and Gastric Cancer Survival 

A phase III study from the United Kingdom has shown that second-line treatment with docetaxel improves overall survival of patients with advanced esophagogastric cancer.1 The strategy has already been...

solid tumors
issues in oncology

Targeted Therapy Gaining Ground in the Second-line Treatment of Gastric Cancer 

In gastric cancer, the concept of targeted therapy assumed clinical significance when the addition of trastuzumab (Herceptin) to chemotherapy improved survival by almost 3 months in the ToGA trial.1 A...

colorectal cancer

Bevacizumab plus Capecitabine Has Robust Effect in Elderly Patients with Colorectal Cancer

In elderly patients with treatment-naive metastatic colorectal cancer, a trend toward a survival benefit was observed for bevacizumab (Avastin) plus capecitabine (Xeloda) in the international phase II...

colorectal cancer

Three Molecular Subtypes of Colorectal Cancer Identified 

Intrinsic molecular subtyping in breast cancer has become clinically applicable, and the same could be happening for gastrointestinal tumors, according to an international study reported at the 2013 G...

hepatobiliary cancer
pancreatic cancer
gastrointestinal cancer

Important Data and Treatment Advances Reported in GIST and in Pancreatic and Liver Cancers 

The 10th annual Gastrointestinal Cancers Symposium, held recently in San Francisco, was jointly sponsored by ASCO, the AGA (American Gastroenterological Association), ASTRO (American Society for Radia...

colorectal cancer

Is Aspirin Protective against Colorectal Cancer? 

A growing body of evidence provides biologic and clinical evidence that nonsteroidal anti-inflammatory agents are protective against colorectal cancer. “It is fascinating for me as a medical oncologi...

Advertisement

Advertisement



Advertisement

click me